Chronic kidney disease is a key risk factor for severe COVID-19

Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance o...

Descripción completa

Detalles Bibliográficos
Autores: Ortiz, Alberto|||0000-0002-9805-9523, Cozzolino, Mario|||0000-0002-8494-6252, Duivenvoorden, Raphaël, Fliser, Danilo, Fouque, Denis, Franssen, Casper F.M., Goumenos, Dimitrios, Hemmelder, Marc H., Hilbrands, Luuk B.|||0000-0002-4935-9765, Jager, Kitty|||0000-0003-0444-8569, Massy, Ziad A., Noordzij, Marlies, Rosenkranz, Alexander R., Rychlık, Ivan, Soler, Maria Jose, Stevens, Kate|||0000-0003-2291-1692, Torra Balcells, Roser|||0000-0001-8714-2332, Tuglular, Serhan, Vart, Priya, Wanner, Christoph|||0000-0001-9507-5301, Gansevoort, Ron T.|||0000-0002-3223-0906
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:272158
Acceso en línea:https://ddd.uab.cat/record/272158
https://dx.doi.org/urn:doi:10.1093/NDT/GFAA314
Access Level:acceso abierto
Palabra clave:Chronic kidney disease
COVID-19
Mortality
Prevalence
Renal replacement therapy
Risk factor
id ES_7849bc37dbd6d239596f93eb0e90b4e0
oai_identifier_str oai:ddd.uab.cat:272158
network_acronym_str ES
network_name_str España
repository_id_str
spelling Chronic kidney disease is a key risk factor for severe COVID-19A call to action by the ERA-edtaOrtiz, Alberto|||0000-0002-9805-9523Cozzolino, Mario|||0000-0002-8494-6252Duivenvoorden, RaphaëlFliser, DaniloFouque, DenisFranssen, Casper F.M.Goumenos, DimitriosHemmelder, Marc H.Hilbrands, Luuk B.|||0000-0002-4935-9765Jager, Kitty|||0000-0003-0444-8569Massy, Ziad A.Noordzij, MarliesRosenkranz, Alexander R.Rychlık, IvanSoler, Maria JoseStevens, Kate|||0000-0003-2291-1692Torra Balcells, Roser|||0000-0001-8714-2332Tuglular, SerhanVart, PriyaWanner, Christoph|||0000-0001-9507-5301Gansevoort, Ron T.|||0000-0002-3223-0906Chronic kidney diseaseCOVID-19MortalityPrevalenceRenal replacement therapyRisk factorDiabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria. As the disease spread across the globe, information on larger populations with greater granularity on risk factors emerged. The recently published OpenSAFELY project analysed factors associated with COVID-19 death in 17 million patients. The picture that arose differs significantly from initial reports. For example, hypertension is not an independent risk factor for COVID-19 death [adjusted hazard ratio (aHR) 0.89], but renal disease very much is. Dialysis (aHR 3.69), organ transplantation (aHR 3.53) and CKD (aHR 2.52 for patients with eGFR <30 mL/min/1.73 m) represent three of the four comorbidities associated with the highest mortality risk from COVID-19. The risk associated with CKD Stages 4 and 5 is higher than the risk associated with diabetes mellitus (aHR range 1.31-1.95, depending upon glycaemic control) or chronic heart disease (aHR 1.17). In another recent publication, the Global Burden of Disease collaboration identified that worldwide, CKD is the most prevalent risk factor for severe COVID-19. Moreover, the distribution of risk factors for COVID-19 mortality appears to be different in patients with CKD when compared with the general population. The high prevalence of CKD in combination with the elevated risk of mortality from COVID-19 in CKD necessitates urgent action for this group of patients. This article defines essential action points (summarized in Box 1), among which is advocating the inclusion of CKD patients in clinical trials testing the efficacy of drugs and vaccines to prevent severe COVID-19.Universitat Autònoma de Barcelona 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/272158https://dx.doi.org/urn:doi:10.1093/NDT/GFAA314reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD016/0009open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2721582026-06-06T12:50:31Z
dc.title.none.fl_str_mv Chronic kidney disease is a key risk factor for severe COVID-19
A call to action by the ERA-edta
title Chronic kidney disease is a key risk factor for severe COVID-19
spellingShingle Chronic kidney disease is a key risk factor for severe COVID-19
Ortiz, Alberto|||0000-0002-9805-9523
Chronic kidney disease
COVID-19
Mortality
Prevalence
Renal replacement therapy
Risk factor
title_short Chronic kidney disease is a key risk factor for severe COVID-19
title_full Chronic kidney disease is a key risk factor for severe COVID-19
title_fullStr Chronic kidney disease is a key risk factor for severe COVID-19
title_full_unstemmed Chronic kidney disease is a key risk factor for severe COVID-19
title_sort Chronic kidney disease is a key risk factor for severe COVID-19
dc.creator.none.fl_str_mv Ortiz, Alberto|||0000-0002-9805-9523
Cozzolino, Mario|||0000-0002-8494-6252
Duivenvoorden, Raphaël
Fliser, Danilo
Fouque, Denis
Franssen, Casper F.M.
Goumenos, Dimitrios
Hemmelder, Marc H.
Hilbrands, Luuk B.|||0000-0002-4935-9765
Jager, Kitty|||0000-0003-0444-8569
Massy, Ziad A.
Noordzij, Marlies
Rosenkranz, Alexander R.
Rychlık, Ivan
Soler, Maria Jose
Stevens, Kate|||0000-0003-2291-1692
Torra Balcells, Roser|||0000-0001-8714-2332
Tuglular, Serhan
Vart, Priya
Wanner, Christoph|||0000-0001-9507-5301
Gansevoort, Ron T.|||0000-0002-3223-0906
author Ortiz, Alberto|||0000-0002-9805-9523
author_facet Ortiz, Alberto|||0000-0002-9805-9523
Cozzolino, Mario|||0000-0002-8494-6252
Duivenvoorden, Raphaël
Fliser, Danilo
Fouque, Denis
Franssen, Casper F.M.
Goumenos, Dimitrios
Hemmelder, Marc H.
Hilbrands, Luuk B.|||0000-0002-4935-9765
Jager, Kitty|||0000-0003-0444-8569
Massy, Ziad A.
Noordzij, Marlies
Rosenkranz, Alexander R.
Rychlık, Ivan
Soler, Maria Jose
Stevens, Kate|||0000-0003-2291-1692
Torra Balcells, Roser|||0000-0001-8714-2332
Tuglular, Serhan
Vart, Priya
Wanner, Christoph|||0000-0001-9507-5301
Gansevoort, Ron T.|||0000-0002-3223-0906
author_role author
author2 Cozzolino, Mario|||0000-0002-8494-6252
Duivenvoorden, Raphaël
Fliser, Danilo
Fouque, Denis
Franssen, Casper F.M.
Goumenos, Dimitrios
Hemmelder, Marc H.
Hilbrands, Luuk B.|||0000-0002-4935-9765
Jager, Kitty|||0000-0003-0444-8569
Massy, Ziad A.
Noordzij, Marlies
Rosenkranz, Alexander R.
Rychlık, Ivan
Soler, Maria Jose
Stevens, Kate|||0000-0003-2291-1692
Torra Balcells, Roser|||0000-0001-8714-2332
Tuglular, Serhan
Vart, Priya
Wanner, Christoph|||0000-0001-9507-5301
Gansevoort, Ron T.|||0000-0002-3223-0906
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Chronic kidney disease
COVID-19
Mortality
Prevalence
Renal replacement therapy
Risk factor
topic Chronic kidney disease
COVID-19
Mortality
Prevalence
Renal replacement therapy
Risk factor
description Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria. As the disease spread across the globe, information on larger populations with greater granularity on risk factors emerged. The recently published OpenSAFELY project analysed factors associated with COVID-19 death in 17 million patients. The picture that arose differs significantly from initial reports. For example, hypertension is not an independent risk factor for COVID-19 death [adjusted hazard ratio (aHR) 0.89], but renal disease very much is. Dialysis (aHR 3.69), organ transplantation (aHR 3.53) and CKD (aHR 2.52 for patients with eGFR <30 mL/min/1.73 m) represent three of the four comorbidities associated with the highest mortality risk from COVID-19. The risk associated with CKD Stages 4 and 5 is higher than the risk associated with diabetes mellitus (aHR range 1.31-1.95, depending upon glycaemic control) or chronic heart disease (aHR 1.17). In another recent publication, the Global Burden of Disease collaboration identified that worldwide, CKD is the most prevalent risk factor for severe COVID-19. Moreover, the distribution of risk factors for COVID-19 mortality appears to be different in patients with CKD when compared with the general population. The high prevalence of CKD in combination with the elevated risk of mortality from COVID-19 in CKD necessitates urgent action for this group of patients. This article defines essential action points (summarized in Box 1), among which is advocating the inclusion of CKD patients in clinical trials testing the efficacy of drugs and vaccines to prevent severe COVID-19.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/272158
https://dx.doi.org/urn:doi:10.1093/NDT/GFAA314
url https://ddd.uab.cat/record/272158
https://dx.doi.org/urn:doi:10.1093/NDT/GFAA314
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD016/0009
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411197716004864
score 15,301629

Similares en LA Referencia